2024
Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study
Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D, Rigotti N, Siedner M, Wood R, Paltiel A, Freedberg K, Hyle E, Reddy K. Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study. Journal Of The International AIDS Society 2024, 27: e26315. PMID: 38924347, PMCID: PMC11197963, DOI: 10.1002/jia2.26315.Peer-Reviewed Original ResearchConceptsMortality hazard ratioSmoking cessationLife yearsNever smoking statusLife expectancyVirologically suppressed PWHSmoking statusTobacco smokeIntegrate tobacco cessation interventionsMortality riskHazard ratioTobacco cessation interventionsSmoking cessation increasesTobacco-related illnessesImpact of tobacco smokingAntiretroviral therapyMortality risk increaseProportion of deathsChronic respiratory conditionsImpact of smokingCohort of PWHVirological non-suppressionCessation interventionsVirologic suppressionHIV care
2023
965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. 965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee. Open Forum Infectious Diseases 2023, 10: ofad500.2460. PMCID: PMC10678140, DOI: 10.1093/ofid/ofad500.2460.Peer-Reviewed Original ResearchHIV testingHIV prevention fundingHIV transmissionDeath avertedTransgender womenPregnant peopleHIV careRisk groupsCondom usePrevention fundingHIV testing ratesPre-exposure prophylaxisHIV testing frequencyPriority risk groupBlack womenHeterosexual Black womenNumber of peoplePrEP provisionVirologic suppressionIncident HIVUndiagnosed HIVHIV deathsPrEP usePotential ClinicalClinical impactDaily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price
Amick A, Eskibozkurt G, Hosek S, Flanagan C, Landovitz R, Jin E, Wilson C, Freedberg K, Weinstein M, Kazemian P, Paltiel A, Ciaranello A, Neilan A. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clinical Infectious Diseases 2023, 78: 402-410. PMID: 37823865, PMCID: PMC10874274, DOI: 10.1093/cid/ciad566.Peer-Reviewed Original ResearchPre-exposure prophylaxisHIV incidenceRisk of HIVOral PrEPAnnual screeningHuman immunodeficiency virus (HIV) pre-exposure prophylaxisOral HIV pre-exposure prophylaxisHIV pre-exposure prophylaxisIncremental cost-effectiveness ratioHIV RNA levelsYoung menCost-effectiveness ratioAnnual HIVHigher discontinuationPrEP retentionAntiretroviral therapyDrug pricesHIV careLow adherenceLifetime horizonNew infectionsHIVIncidencePrEPRNA levels
2018
The cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil
Luz PM, Osher B, Grinsztejn B, Maclean RL, Losina E, Stern ME, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, Walensky RP, Veloso VG, Paltiel AD. The cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Journal Of The International AIDS Society 2018, 21: e25096. PMID: 29603888, PMCID: PMC5878414, DOI: 10.1002/jia2.25096.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHIV infectionTransgender womenPrEP effectivenessHigh riskMedical costsPre-exposure prophylaxis programHIV pre-exposure prophylaxisAnnual HIV incidenceUniversal ART accessPre-exposure prophylaxisHIV testing frequencyDirect medical costsHigh-risk MSMLife expectancyHIV infection riskUndiscounted life expectancyCost-effectiveness ratioYears of lifeUnited States dollarsHIV careHIV incidenceMean ageProphylaxis programART access
2017
A Flow-Based Model of the HIV Care Continuum in the United States
Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Tang T, Hall HI, Kaplan EH. A Flow-Based Model of the HIV Care Continuum in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 548-553. PMID: 28471841, PMCID: PMC5533168, DOI: 10.1097/qai.0000000000001429.Peer-Reviewed Original ResearchConceptsViral suppressionAntiretroviral therapyHIV careNorth American AIDS Cohort CollaborationProportion of HIVHIV care continuumCohort CollaborationHIV diagnosisAntiretroviral treatmentVirological dataCare continuumFlow of patientsDisease controlPatientsCareAverage timeHIVTherapyLaboratory resultsMonthsSuppressionYearsDiagnosisIndividualsPrevention
2015
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US
Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Research & Clinical Practice 2015, 16: 207-218. PMID: 26651525, PMCID: PMC4718767, DOI: 10.1080/15284336.2015.1123942.Peer-Reviewed Original ResearchConceptsGeneric antiretroviral therapyAntiretroviral therapyProbabilistic sensitivity analysesTreatment changesFirst-line ART regimensMore treatment changesComparative effectiveness trialTwo-arm trialImproved health outcomesTwo-pillART regimensHIV careART failureEffectiveness trialTrial completionRNA suppressionHealth outcomesFuture patientsPatientsCost-effective strategyTrialsRegimenRegimensHIVTherapy
2010
Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis
Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. Value In Health 2010, 13: 893-902. PMID: 20950323, PMCID: PMC2999642, DOI: 10.1111/j.1524-4733.2010.00763.x.Peer-Reviewed Original ResearchConceptsHIV screeningEarly treatment goalsNew HIV casesFrequency of screeningBudget impact analysisTotal budget increasesHIV careAnnual incidenceHIV casesHIV prevalenceCDC estimatesUS CentersTreatment goalsBudget impactTreatment programDisease controlHIVTest characteristicsTreatment costsFinancial burdenCareScreeningSmall proportionProgram savingsFund care
2009
Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival loss
2002
AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States
Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States. Clinical Infectious Diseases 2002, 35: 606-610. PMID: 12173137, DOI: 10.1086/341903.Peer-Reviewed Original ResearchConceptsEffective antiretroviral therapyHuman immunodeficiency virusDrug Assistance ProgramsCost-effectiveness analysisAntiretroviral therapyHIV careMedication costsImmunodeficiency virusOutpatient arenaDisease outcomePatient's placePrivate health insuranceHealth careHealth insurancePatientsAIDSCareUnited StatesMedicationsHIVInpatientsTherapyMedicaidLifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy 2002, 7: 257-266. PMID: 12553480, DOI: 10.1177/135965350200700405.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyHIV infectionCD4 strataAntiretroviral therapyHIV careHIV diseaseLifetime costsHighly Active Antiretroviral TherapyHigher CD4 strataHIV Clinical CohortLowest CD4 stratumCD4 cell countEra of HAARTBurden of diseaseStage of illnessCost of careHealth policy plannersHealth care costsClinical managementSpecific AIDSClinical cohortMean costFrench patientsCare costsCell count